Lawsuits alleging health and financial injury from the anti-blood-clot drug Plavix are piling up in New Jersey following the U.S. Judicial Panel on Multi-District Litigation’s decision to centralize them here.

There are 73 cases pending under the caption In re Plavix Product Liability and Marketing Litigation, MDL-2418, and the MDL panel on Thursday was considering the transfer of another 14.